BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33798787)

  • 1. Hypoxia via ERK Signaling Inhibits Hepatic PPARα to Promote Fatty Liver.
    Mooli RGR; Rodriguez J; Takahashi S; Solanki S; Gonzalez FJ; Ramakrishnan SK; Shah YM
    Cell Mol Gastroenterol Hepatol; 2021; 12(2):585-597. PubMed ID: 33798787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia exacerbates nonalcoholic fatty liver disease via the HIF-2α/PPARα pathway.
    Chen J; Chen J; Fu H; Li Y; Wang L; Luo S; Lu H
    Am J Physiol Endocrinol Metab; 2019 Oct; 317(4):E710-E722. PubMed ID: 31430204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease.
    Li Y; Chen M; Zhou Y; Tang C; Zhang W; Zhong Y; Chen Y; Zhou H; Sheng L
    Theranostics; 2020; 10(8):3579-3593. PubMed ID: 32206109
    [No Abstract]   [Full Text] [Related]  

  • 4. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis.
    Svegliati-Baroni G; Saccomanno S; Rychlicki C; Agostinelli L; De Minicis S; Candelaresi C; Faraci G; Pacetti D; Vivarelli M; Nicolini D; Garelli P; Casini A; Manco M; Mingrone G; Risaliti A; Frega GN; Benedetti A; Gastaldelli A
    Liver Int; 2011 Oct; 31(9):1285-97. PubMed ID: 21745271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HIF-2α/PPARα pathway is essential for liraglutide-alleviated, lipid-induced hepatic steatosis.
    Wang H; Wang L; Li Y; Luo S; Ye J; Lu Z; Li X; Lu H
    Biomed Pharmacother; 2021 Aug; 140():111778. PubMed ID: 34062416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium butyrate alleviates free fatty acid-induced steatosis in primary chicken hepatocytes via the AMPK/PPARα pathway.
    Ding J; Liu J; Chen J; Cheng X; Cao H; Guo X; Hu G; Zhuang Y
    Poult Sci; 2024 Apr; 103(4):103482. PubMed ID: 38387286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.
    Huang K; Du M; Tan X; Yang L; Li X; Jiang Y; Wang C; Zhang F; Zhu F; Cheng M; Yang Q; Yu L; Wang L; Huang D; Huang K
    J Hepatol; 2017 May; 66(5):962-977. PubMed ID: 27979751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-option of PPARα in the regulation of lipogenesis and fatty acid oxidation in CLA-induced hepatic steatosis.
    Cai D; Li Y; Zhang K; Zhou B; Guo F; Holm L; Liu HY
    J Cell Physiol; 2021 Jun; 236(6):4387-4402. PubMed ID: 33184849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD.
    Montagner A; Polizzi A; Fouché E; Ducheix S; Lippi Y; Lasserre F; Barquissau V; Régnier M; Lukowicz C; Benhamed F; Iroz A; Bertrand-Michel J; Al Saati T; Cano P; Mselli-Lakhal L; Mithieux G; Rajas F; Lagarrigue S; Pineau T; Loiseau N; Postic C; Langin D; Wahli W; Guillou H
    Gut; 2016 Jul; 65(7):1202-14. PubMed ID: 26838599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDKN2A/p16INK4a suppresses hepatic fatty acid oxidation through the AMPKα2-SIRT1-PPARα signaling pathway.
    Deleye Y; Cotte AK; Hannou SA; Hennuyer N; Bernard L; Derudas B; Caron S; Legry V; Vallez E; Dorchies E; Martin N; Lancel S; Annicotte JS; Bantubungi K; Pourtier A; Raverdy V; Pattou F; Lefebvre P; Abbadie C; Staels B; Haas JT; Paumelle R
    J Biol Chem; 2020 Dec; 295(50):17310-17322. PubMed ID: 33037071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant miR199a-5p/caveolin1/PPARα axis in hepatic steatosis.
    Li B; Zhang Z; Zhang H; Quan K; Lu Y; Cai D; Ning G
    J Mol Endocrinol; 2014 Dec; 53(3):393-403. PubMed ID: 25312970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARα pathway.
    Huang Y; Lang H; Chen K; Zhang Y; Gao Y; Ran L; Yi L; Mi M; Zhang Q
    Appl Physiol Nutr Metab; 2020 Mar; 45(3):227-239. PubMed ID: 31173696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PPARα (Peroxisome Proliferator-activated Receptor α) Activation Reduces Hepatic CEACAM1 Protein Expression to Regulate Fatty Acid Oxidation during Fasting-refeeding Transition.
    Ramakrishnan SK; Khuder SS; Al-Share QY; Russo L; Abdallah SL; Patel PR; Heinrich G; Muturi HT; Mopidevi BR; Oyarce AM; Shah YM; Sanchez ER; Najjar SM
    J Biol Chem; 2016 Apr; 291(15):8121-9. PubMed ID: 26846848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIF-1α and HIF-2α are critically involved in hypoxia-induced lipid accumulation in hepatocytes through reducing PGC-1α-mediated fatty acid β-oxidation.
    Liu Y; Ma Z; Zhao C; Wang Y; Wu G; Xiao J; McClain CJ; Li X; Feng W
    Toxicol Lett; 2014 Apr; 226(2):117-23. PubMed ID: 24503013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TAK1-mediated autophagy and fatty acid oxidation prevent hepatosteatosis and tumorigenesis.
    Inokuchi-Shimizu S; Park EJ; Roh YS; Yang L; Zhang B; Song J; Liang S; Pimienta M; Taniguchi K; Wu X; Asahina K; Lagakos W; Mackey MR; Akira S; Ellisman MH; Sears DD; Olefsky JM; Karin M; Brenner DA; Seki E
    J Clin Invest; 2014 Aug; 124(8):3566-78. PubMed ID: 24983318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic ATF6 Increases Fatty Acid Oxidation to Attenuate Hepatic Steatosis in Mice Through Peroxisome Proliferator-Activated Receptor α.
    Chen X; Zhang F; Gong Q; Cui A; Zhuo S; Hu Z; Han Y; Gao J; Sun Y; Liu Z; Yang Z; Le Y; Gao X; Dong LQ; Gao X; Li Y
    Diabetes; 2016 Jul; 65(7):1904-15. PubMed ID: 27207533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocyte Peroxisome Proliferator-Activated Receptor α Enhances Liver Regeneration after Partial Hepatectomy in Mice.
    Xie G; Yin S; Zhang Z; Qi D; Wang X; Kim D; Yagai T; Brocker CN; Wang Y; Gonzalez FJ; Wang H; Qu A
    Am J Pathol; 2019 Feb; 189(2):272-282. PubMed ID: 30448405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nordihydroguaiaretic acid improves metabolic dysregulation and aberrant hepatic lipid metabolism in mice by both PPARα-dependent and -independent pathways.
    Zhang H; Shen WJ; Cortez Y; Kraemer FB; Azhar S
    Am J Physiol Gastrointest Liver Physiol; 2013 Jan; 304(1):G72-86. PubMed ID: 23104557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Puerarin ameliorates hepatic steatosis by activating the PPARα and AMPK signaling pathways in hepatocytes.
    Kang OH; Kim SB; Mun SH; Seo YS; Hwang HC; Lee YM; Lee HS; Kang DG; Kwon DY
    Int J Mol Med; 2015 Mar; 35(3):803-9. PubMed ID: 25605057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of diet-induced hepatic steatosis by peripheral CB1 receptor blockade in mice is p53/miRNA-22/SIRT1/PPARα dependent.
    Azar S; Udi S; Drori A; Hadar R; Nemirovski A; Vemuri KV; Miller M; Sherill-Rofe D; Arad Y; Gur-Wahnon D; Li X; Makriyannis A; Ben-Zvi D; Tabach Y; Ben-Dov IZ; Tam J
    Mol Metab; 2020 Dec; 42():101087. PubMed ID: 32987186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.